This site is intended for U.S. healthcare professionals.
ATTR-CM is a progressive, fatal disease, so early diagnosis is critical2-5
It’s more common than you think2
Proven to reduce all-cause mortality and CV-related hospitalization6
Watch an in-depth video featuring peer perspectives from Dr Christopher Pray (St Clair Health, Pittsburgh, PA) and Dr Fernando Mendoza (UC Irvine, Irvine, CA) on the importance of ruling out ATTR cardiac amyloidosis in patients with heart failure
Register to learn more from your peers
Find out about ATTR-CM, VYNDAMAX, and access
Dive deeper into ATTR-CM and VYNDAMAX data
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.